European Regulators Recommend Janssen’s Imbruvica
The European regulatory body has granted approval to Pharmacyclics’ / Johnson & Johnson’s Janssen unit’s Imbruvica for two types of blood cancer. The European Commission has specifically approved the drug for mantle cell lymphoma (MCL) or patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or first-line in those with